PHOSPHATIDYLCHOLINE

OTHER NAME(S):

1,2-diacyl-sn-glycero-3-phosphocholine, Fosfatidilcolina, Lipodissolve, Lipolight, Lipolyse, Lipothérapie, Lipotherapy, Phosphatidyl Choline, Phospholipid, Phospholipide, Phospholipon, Polyenylphosphatidylcholine, Polyénylphosphatidylcholine, PtdCho.<br/><br/>

Overview

Overview Information

Phosphatidylcholine is a chemical contained in eggs, soybeans, mustard, sunflower, and other foods. It is found naturally in the body in all cells.

The term "phosphatidylcholine" is sometimes used interchangeably with "lecithin," although the two are different. Choline is a component of phosphatidylcholine, which is a component of lecithin. Although closely related, these terms are not the same.

There is some interest in using phosphatidylcholine to improve symptoms of ulcerative colitis in some people. Some scientific research supports this use.

Because the body uses phosphatidylcholine to make a brain chemical called acetylcholine, there is also some interest in using it for treating "brain-centered" conditions such as memory loss, Alzheimer’s disease, anxiety, manic-depressive disorders, and a movement disorder called tardive dyskinesia. But there is limited scientific evidence to support these uses.

Phosphatidylcholine is the primary active ingredient contained in cosmetic injection products used to "dissolve" fat. These products include Lipodissolve, Lipolight, Lipolyse, Lipotherapy, and others. Some cosmetic centers in several countries initially imported a prescription intravenous drug product from Germany known as Lipostabil. They used it subcutaneously for cosmetic purposes; however, the manufacturer of this product does not promote it for this use due to lack of reliable evidence. Some countries, such as Brazil, have banned importation of this product for cosmetic use. The U.S. Food and Drug Administration (FDA) has also issued a warning to sellers of Lipostabil for making false and misleading claims and because it is an unapproved drug in the U.S.

Phosphatidylcholine injections are now often compounded in pharmacies. However, in the U.S., phosphatidylcholine, when compounded and used as an injection, is considered an unapproved drug rather than a dietary supplement.

How does it work?

The body makes a brain chemical called acetylcholine from phosphatidylcholine. Acetylcholine is important for memory and other bodily functions. Since phosphatidylcholine might increase acetylcholine, there is interest in using it for improving memory and for conditions such as Alzheimer's disease.

Some researchers think phosphatidylcholine acts like a detergent and breaks down fat.

A certain form of phosphatidylcholine (polyunsaturated phosphatidylcholine) might provide protection against liver fibrosis and liver damage caused by drinking alcohol, although the exact mechanisms are not completely understood.

Phosphatidylcholine might also help to protect the wall of the large intestine in people with a condition known as ulcerative colitis.

Uses

Uses & Effectiveness?

Possibly Effective for

  • Inflammatory bowel disease (ulcerative colitis). Research suggests that taking various types of phosphatidylcholine daily for up to 3 months improves symptoms in people with ulcerative colitis.

Possibly Ineffective for

  • Hepatitis A. Taking phosphatidylcholine by mouth does not seem to improve liver function in people with hepatitis A.
  • Infant development. Taking phosphatidylcholine during pregnancy does not seem to improve the brain development of the infant.
  • Improving a medical procedure called peritoneal dialysis. Taking phosphatidylcholine by mouth does not seem to improve a medical procedure called peritoneal dialysis.
  • A movement disorder called tardive dyskinesia. Taking phosphatidylcholine by mouth does not seem to improve a movement disorder called tardive dyskinesia.

Insufficient Evidence for

  • Acne. Early research suggests that applying a cream containing 4% niacinamide and phosphatidylcholine to the skin seems to improve acne in some people.
  • Liver disease caused by alcohol. Early research suggests that taking phosphatidylcholine daily for 24 months does not increase survival in people with liver disease caused by drinking alcohol.
  • Reducing fat deposits. Early research suggests that injections of phosphatidylcholine under the skin may make fatty deposits on the chin, thigh, hips, abdomen, back, neck, and elsewhere look smaller to some people. Improvements appear to last for 2-3 years or longer. In one study, 80% of patients reported improvements in facial fat that lasted for up to 3 years. However, these results have been questioned because the studies were not well designed.
  • Declining brain function caused by liver disease. Research suggests that taking phosphatidylcholine daily for 6-8 weeks does not improve declining brain function in people with liver disease or liver failure.
  • Hepatitis B. Studies regarding hepatitis B show conflicting results. It is not clear if phosphatidylcholine is beneficial.
  • Hepatitis C. Early research suggests that taking phosphatidylcholine by mouth, together with interferon, seems to improve liver function in people with hepatitis C.
  • Inability to break down cholesterol in the body. Early research suggests that taking phosphatidylcholine does not reduce cholesterol levels in the body of people who are unable to break down cholesterol
  • Treating non-cancerous fatty tumors (lipomas). There is one report that injecting a phosphatidylcholine solution directly into a lipoma can shrink the tumor by about 35%. However, this treatment might cause an unwanted reaction in the lipoma.
  • Liver disease not related to alcohol use (nonalcoholic fatty liver disease; NAFLD). Early research suggests that taking a product containing phosphatidylcholine, along with vitamin E, and silybin, a chemical in milk thistle might improve liver function in people with the liver disease known as NAFLD.
  • Memory loss. There is early evidence that taking a single 25 mg dose of phosphatidylcholine can improve some measures of memory in healthy college students.
  • Eyelid fat. There is some evidence that injecting a phosphatidylcholine solution reduces bulging lower eyelid fat pads in some people.
  • Anxiety.
  • Eczema.
  • Gallbladder disease.
  • Manic-depressive illness.
  • Circulation disorders of the arms and legs.
  • Weight loss.
  • Premenstrual syndrome (PMS).
  • Alzheimer's disease.
  • Depressed immunity.
  • Preventing aging.
  • Other conditions.
More evidence is needed to rate the effectiveness of phosphatidylcholine for these uses.

Side Effects

Side Effects & Safety

Phosphatidylcholine is POSSIBLY SAFE when taken by mouth, when injected just beneath the skin, or when applied on the skin short-term. The safety of long-term use is not known.

When phosphatidylcholine is taken by mouth, it can sometimes cause excessive sweating, stomach upset, and diarrhea.

Phosphatidylcholine injections can cause irritation, swelling, redness, itching, burning, bruising, and pain at the injection site. These side effects usually go away over a period of several days. Sometimes, phosphatidylcholine might cause gastrointestinal upset, like bloating, diarrhea, and nausea.

If phosphatidylcholine is injected directly into a fatty growth (lipoma), it might cause an inflammatory reaction that could make the tumor more fibrous. In one reported case, the patient who had this done had to have the lipoma removed by surgery.

Special Precautions & Warnings:

Pregnancy: Phosphatidylcholine is POSSIBLY SAFE when taken by mouth Breast-feeding: There is not enough reliable information about the safety of taking phosphatidylcholine when you are breast feeding. Stay on the safe side and avoid use.

Interactions

Interactions?

Moderate Interaction

Be cautious with this combination

!
  • Drying medications (Anticholinergic drugs) interacts with PHOSPHATIDYLCHOLINE

    Some drying medications are called anticholinergic drugs. Phosphatidylcholine might increase chemicals that can decrease the effects of these drying medications.<br/><br/> Some drying medications include atropine, scopolamine, and some medications used for allergies (antihistamines) and for depression (antidepressants).

  • Medications for Alzheimer's disease (Acetylcholinesterase (AChE) inhibitors) interacts with PHOSPHATIDYLCHOLINE

    Phosphatidylcholine might increase a chemical in the body called acetylcholine. Medications for Alzheimer's called acetylcholinesterase inhibitors also increase the chemical acetylcholine. Taking phosphatidylcholine along with medications for Alzheimer's disease might increase effects and side effects of medications for Alzheimer's disease.<br/><br/> Some medications called acetylcholinesterase inhibitors include donepezil (Aricept), tacrine (Cognex), rivastigmine (Exelon), and galantamine (Reminyl, Razadyne).

  • Various medications used for glaucoma, Alzheimer's disease, and other conditions (Cholinergic drugs) interacts with PHOSPHATIDYLCHOLINE

    Phosphatidylcholine might increase a chemical in the body called acetylcholine. This chemical is similar to some medications used for glaucoma, Alzheimer's disease, and other conditions. Taking phosphatidylcholine with these medications might increase the chance of side effects.<br/><br/> Some of these medications used for glaucoma, Alzheimer's disease, and other conditions include pilocarpine (Pilocar and others), and others.

Dosing

Dosing

The following doses have been studied in scientific research:

ADULTS

BY MOUTH:

  • Ulcerative colitis: 1-6 grams daily taken in divided doses.

View References

REFERENCES:

  • Guo, H., Ekusa, A., Iwai, K., Yonekura, M., Takahata, Y., and Morimatsu, F. Royal jelly peptides inhibit lipid peroxidation in vitro and in vivo. J.Nutr.Sci.Vitaminol.(Tokyo) 2008;54(3):191-195. View abstract.
  • Guo, H., Saiga, A., Sato, M., Miyazawa, I., Shibata, M., Takahata, Y., and Morimatsu, F. Royal jelly supplementation improves lipoprotein metabolism in humans. J.Nutr.Sci.Vitaminol.(Tokyo) 2007;53(4):345-348. View abstract.
  • Hamerlinck, F. F. Neopterin: a review. Exp.Dermatol. 1999;8(3):167-176. View abstract.
  • Hammerl, H. and Pichler O. Vorlfiufiger Bericht tiber die Behandlung der Arteriosclerose mit Gelee Royale-Holzinger. Z.Med. 1957;13-14:364.
  • Hammerl, H. Pichler O. Zur Therapie mit Apffortyl. Medsche Klin. 1960;45:2015-2021.
  • Harada, S., Moriyama, T., and Tanaka, A. [Two cases of royal jelly allergy provoked the symptoms at the time of their first intake]. Arerugi 2011;60(6):708-713. View abstract.
  • Harwood, M., Harding, S., Beasley, R., and Frankish, P. D. Asthma following royal jelly. N.Z.Med.J. 8-23-1996;109(1028):325. View abstract.
  • Hattori, N., Nomoto, H., Fukumitsu, H., Mishima, S., and Furukawa, S. Royal jelly and its unique fatty acid, 10-hydroxy-trans-2-decenoic acid, promote neurogenesis by neural stem/progenitor cells in vitro. Biomed.Res. 2007;28(5):261-266. View abstract.
  • Inoue, S., Koya-Miyata, S., Ushio, S., Iwaki, K., Ikeda, M., and Kurimoto, M. Royal Jelly prolongs the life span of C3H/HeJ mice: correlation with reduced DNA damage. Exp.Gerontol. 2003;38(9):965-969. View abstract.
  • Kaczor, M. Koltek A. and Matuszewski J. The effect of Royal Jelly on blood lipids in atheromatic subjects. Polski Tygod.tek. 1962;17:140-144.
  • Kamakura, M., Mitani, N., Fukuda, T., and Fukushima, M. Antifatigue effect of fresh royal jelly in mice. J.Nutr.Sci.Vitaminol.(Tokyo) 2001;47(6):394-401. View abstract.
  • Kamakura, M., Moriyama, T., and Sakaki, T. Changes in hepatic gene expression associated with the hypocholesterolaemic activity of royal jelly. J.Pharm.Pharmacol. 2006;58(12):1683-1689. View abstract.
  • Kanbur, M., Eraslan, G., Beyaz, L., Silici, S., Liman, B. C., Altinordulu, S., and Atasever, A. The effects of royal jelly on liver damage induced by paracetamol in mice. Exp.Toxicol.Pathol. 2009;61(2):123-132. View abstract.
  • Katayama, M., Aoki, M., and Kawana, S. Case of anaphylaxis caused by ingestion of royal jelly. J.Dermatol. 2008;35(4):222-224. View abstract.
  • King, D. S., Baskerville, R., Hellsten, Y., Senchina, D. S., Burke, L. M., Stear, S. J., and Castell, L. M. A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance-Part 34. Br.J.Sports Med. 2012;46(9):689-690. View abstract.
  • Knol, R. J., Doornbos, T., van den Bos, J. C., de, Bruin K., Pfaffendorf, M., Aanhaanen, W., Janssen, A. G., Vekemans, J. A., van Eck-Smit, B. L., and Booij, J. Synthesis and evaluation of iodinated TZTP-derivatives as potential radioligands for imaging of muscarinic M2 receptors with SPET. Nucl.Med.Biol. 2004;31(1):111-123. View abstract.
  • Kolarov, G., Nalbanski, B., Kamenov, Z., Orbetsova, M., Georgiev, S., Nikolov, A., and Marinov, B. [Possibilities for an individualized approach to the treatment of climacteric symptoms with phytoestrogens]. Akush.Ginekol.(Sofiia) 2001;40(4):18-21. View abstract.
  • Koya-Miyata, S., Okamoto, I., Ushio, S., Iwaki, K., Ikeda, M., and Kurimoto, M. Identification of a collagen production-promoting factor from an extract of royal jelly and its possible mechanism. Biosci.Biotechnol.Biochem. 2004;68(4):767-773. View abstract.
  • Kristoffersen, K., Thomsen, B. W., Schacke, E., and Wagner, H. H. [Use of natural medicines in women referred to specialists]. Ugeskr.Laeger 1-13-1997;159(3):294-296. View abstract.
  • Laporte, J. R., Ibaanez, L., Vendrell, L., and Ballarin, E. Bronchospasm induced by royal jelly. Allergy 1996;51(6):440. View abstract.
  • Leung, R., Thien, F. C., Baldo, B., and Czarny, D. Royal jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. J.Allergy Clin.Immunol. 1995;96(6 Pt 1):1004-1007. View abstract.
  • Librowski, T Czarnecki R. Comparative analysis of Apistmul Crataegi Forte and royal jelly in the experimental heart action disturbance. Herba Polonica (Poland). 2000;46(145):150.
  • Madar, J., Maly, E., Neubauer, E., and Moscovic, F. [Effect of bee royal jelly (gelee royale) on the cholesterol level, total lipids in the serum and on the fibrinolytic activity of plasma of elderly arteriosclerotic patients]. Z.Alternsforsch. 1965;18(2):103-108. View abstract.
  • Mannoor MK, Shimabukuro I Tsukamotoa M Watanabe H Yamaguchi K Sato Y. Honeybee royal jelly inhibits autoimmunity in SLE-prone NZB × NZW F1 mice. Lupus. 2009;18(1):44-52.
  • Mishima, S., Suzuki, K. M., Isohama, Y., Kuratsu, N., Araki, Y., Inoue, M., and Miyata, T. Royal jelly has estrogenic effects in vitro and in vivo. J.Ethnopharmacol. 10-3-2005;101(1-3):215-220. View abstract.
  • Mizutani, Y., Shibuya, Y., Takahashi, T., Tsunoda, T., Moriyama, T., and Seishima, M. Major royal jelly protein 3 as a possible allergen in royal jelly-induced anaphylaxis. J.Dermatol. 2011;38(11):1079-1081. View abstract.
  • Morita, H., Ikeda, T., Kajita, K., Fujioka, K., Mori, I., Okada, H., Uno, Y., and Ishizuka, T. Effect of royal jelly ingestion for six months on healthy volunteers. Nutr.J. 2012;11:77. View abstract.
  • Munstedt, K., Henschel, M., Hauenschild, A., and von, Georgi R. Royal jelly increases high density lipoprotein levels but in older patients only. J.Altern.Complement Med. 2009;15(4):329-330. View abstract.
  • Nagai, T., Inoue, R., Suzuki, N., and Nagashima, T. Antioxidant properties of enzymatic hydrolysates from royal jelly. J.Med.Food 2006;9(3):363-367. View abstract.
  • Nakaya, M., Onda, H., Sasaki, K., Yukiyoshi, A., Tachibana, H., and Yamada, K. Effect of royal jelly on bisphenol A-induced proliferation of human breast cancer cells. Biosci.Biotechnol.Biochem. 2007;71(1):253-255. View abstract.
  • Nomura M, Maruo N Zamami Y Takatori S Doi S Kawasaki H. Effect of long-term treatment with royal jelly on insulin resistance in Otsuka. Yakugaku Zasshi. 2007;127(11):1877-1882.
  • Okamoto, I., Taniguchi, Y., Kunikata, T., Kohno, K., Iwaki, K., Ikeda, M., and Kurimoto, M. Major royal jelly protein 3 modulates immune responses in vitro and in vivo. Life Sci. 9-5-2003;73(16):2029-2045. View abstract.
  • PAVERO, A. and CAVIGLIA, E. [Royal jelly and its applications in therapy]. Arch.Maragliano.Patol.Clin. 1957;13(4):1023-1033. View abstract.
  • Peacock S. Respiratory distress and royal jelly. BMJ 1995;311(7018):1472.
  • Bartsch, G. G. and Gerber, G. B. Influence of phospholipids on liver damage. II. Changes in lipid content and synthesis after liver damage with carbontetrachloride and other agents. Acta Hepatogastroenterol.(Stuttg) 1975;22(4):228-236. View abstract.
  • Fabia, R., Ar'Rajab, A., Willen, R., Andersson, R., Ahren, B., Larsson, K., and Bengmark, S. Effects of phosphatidylcholine and phosphatidylinositol on acetic-acid-induced colitis in the rat. Digestion 1992;53(1-2):35-44. View abstract.
  • Holecek, M., Mraz, J., Koldova, P., and Skopec, F. Effect of polyunsaturated phosphatidylcholine on liver regeneration onset after hepatectomy in the rat. Arzneimittelforschung. 1992;42(3):337-339. View abstract.
  • Neuberger, J., Hegarty, J. E., Eddleston, A. L., and Williams, R. Effect of polyunsaturated phosphatidylcholine on immune mediated hepatocyte damage. Gut 1983;24(8):751-755. View abstract.
  • Panos, J. M., Palson, R., Johnson, R., Portmann, B., and Williams, R. Polyunsaturated phosphatidylcholine for acute alcoholic hepatitis: a double blind randomized placebo controlled trial. Eur.J.Gastroenterol 1990;2:351-355.
  • Romagosa, R., Saap, L., Givens, M., Salvarrey, A., He, J. L., Hsia, S. L., and Taylor, J. R. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol.Surg. 2000;26(4):338-340. View abstract.
  • Schneider, J., Muller, R., Buberl, W., Kaffarnik, H., Schubotz, R., Hausmann, L., Muhlfellner, G., and Muhlfellner, O. Effect of polyenyl phosphatidyl choline on clofibrate-induced increase in LDL cholesterol. Eur.J.Clin.Pharmacol. 2-19-1979;15(1):15-19. View abstract.
  • Singh, N. K. and Prasad, R. C. A pilot study of polyunsaturated phosphatidyl choline in fulminant and subacute hepatic failure. J Assoc.Physicians India 1998;46(6):530-532. View abstract.
  • Stremmel, W., Merle, U., Zahn, A., Autschbach, F., Hinz, U., and Ehehalt, R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54(7):966-971. View abstract.
  • Zierenberg, O. and Grundy, S. M. Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res 1982;23(8):1136-1142. View abstract.
  • Ablon G, Rotunda AM. Treatment of lower eyelid fat pads using phosphatidylcholine: clinical trial and review. Dermatol Surg 2004;30:422-7. View abstract.
  • Aronson PJ, Lorincz AL. Promotion of palmar sweating with oral phosphatidylcholine. Acta Derm Venereol 1985;65:19-24. View abstract.

Vitamins Survey

Have you ever purchased PHOSPHATIDYLCHOLINE?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

More Resources for PHOSPHATIDYLCHOLINE

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.